<DOC>
	<DOCNO>NCT02800447</DOCNO>
	<brief_summary>1 . To observe compare overall response rate ( ORR ) baseline BEACOPP ABVD regimens patient advance Hodgkin 's lymphoma . 2 . To evaluate safety Natulan® Chinese patient advance Hodgkin 's lymphoma</brief_summary>
	<brief_title>Procarbazine Hydrochloride Capsule ( Natulan® ) Clinical Trial Protocol</brief_title>
	<detailed_description>This confirmatory open-label , randomize , control , multicenter study . Recruited subject randomize treatment group control group , ratio 1:1 . Treatment group accept baseline BEACOPP regimen , control group accept ABVD regimen . The study design consist screen phase 1 week , treatment phase 24 32 week , post treatment follow-up least 2 year .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>The subject age 18~65 , male female ; Newly pathologically diagnose classical Hodgkin 's lymphoma ( lymphocyte depletion type , lymphocyte rich type , nodular sclerosing type , mixed cellularity type ) , accept previous treatment ; Had stage IIB , III IV disease , assess Ann Arbor classification ; ECOG≤2 , life expectancy ≥3 month ; A negative serum pregnancy test require sexually active woman childbearing potential ; The subject voluntarily give write informed consent participate study . Hematopoietic function : Leukocyte &lt; 3,500/mm3（3.5×109/L） Neutrophils &lt; 1,500/mm3（1.5×109/L） Platelets &lt; 100,000/mm3（100×109/L） Intolerance active ingredient and/or excipients study medication ; Severe central nervous system disorder mental illness ; Severe heart disease ( congestive heart failure , uncontrolled hypertension , unstable coronary artery disease , myocardial infarction , severe arrhythmia ) . Echocardiography show rest leave ventricular ejection fraction ( LVEF ) &lt; 50 % ) ; History severe lung disease ; AST ALT＞2.5×ULN，total bilirubin≥1.5×ULN，serum creatinine＞1.5×ULN ( subject liver metastasis : AST ALT &gt; 5xULN , total bilirubin ≥ 3xULN ) ; Uncontrolled , systemic , active infection； Positive serology HIV ; HBsAg positive subject still enrol study , researcher follow `` The consensus Treatment Lymphoma Hepatitis B Infections '' observe closely and/or provide prophylactic antiHBV therapy ( per investigator 's decision ) ; Other previous concomitant malignancy , except basal cell carcinoma and/or cervical carcinoma situ ; The subject receive investigational drug , participate investigational study within 30 day prior screen ; The subject pregnant lactating ; subject childbearing potential ( woman man subject ) want take effective contraceptive measure study period within 3 month study completes ; Investigators believe subject suitable participate study reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>